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The voltage-dependent anion channel (VDAC) is the main interface between the cytosol 
and mitochondria of cells. It plays a crucial role in both mitochondrial metabolism and 
cell death. The main basic function of this channel is to mediate and gate the flux of 
small ions, metabolites, and adenosine triphosphate. Changes in its structure, and thus 
conformation, are expected to affect its activity and modulate the ability of cancer cells 
to expand. In this review, we describe a novel mechanism by which mitochondria of cells 
in hypoxia, a low level of oxygen, protects from apoptosis. In hypoxia, some mitochon-
dria become enlarged due to hyperfusion. These mitochondria possess a truncated 
form of VDAC1 (VDAC1-ΔC), which is linked to the higher metabolic capacity and the 
greater resistance to cell death of hypoxic cells. However, not all of the VDAC1 protein is 
truncated, but the amount of the full-length form is diminished compared to the amount 
in normoxic cells. First, we describe how such a decrease effects cell proliferation, respi-
ration, glycolysis, and other processes. Second, we report on a novel mitochondrial-en-
dolysosomal crosstalk that leads to VDAC1 truncation. By pharmacological targeting of 
VDAC1-ΔC, the production of energy could be turned off and the sensitivity to cell death 
restored. This could counteract the favorable microenvironment that gives cancer cells 
a growth advantage and thereby disrupts the balance between life and death, which is 
controlled by VDAC1.
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inTRODUCTiOn
Mitochondria have evolved over time to take on a symbiotic relationship within eukaryotic cells 
to produce adenosine triphosphate (ATP) through activation of the electron transport chain 
(1). The production of ATP is probably the most important function of mitochondria, together 
with the regulation of apoptosis. Thereby, they are involved in different processes essential to the 
maintenance of cellular homeostasis. Modifications in metabolism and the redox status, critical 
steps in tumor cell transformation and progression, make mitochondria attractive targets for 
therapeutic treatment. Therefore, any modification to cancer cell metabolism and more specifi-
cally to mitochondrial metabolism, by increasing reactive oxygen species (ROS) production, or 
stimulating mitochondrial permeability transition to induce cell death, could be promising new 
therapeutic strategies (2).
How do mitochondria behave in hypoxia? Hypoxia is a decrease in the oxygen concentration 
compared to the normal physiological concentration and is a characteristic of the tumor microenvi-
ronment. Far from being a disadvantage, hypoxia is an undeniable force for the tumor cell. Functional 
benefits of hypoxia include epigenetic modifications, tumor vascularization, modified metabolism, 
signaling of metastasis, invasion and extravasation, cancer stemness, and innate immune activation, 
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all of which are under the control of complex molecular pathways 
driven by the transcription factor the hypoxia-inducible factor 
(HIF) (3, 4). These changes help cells to proliferate and resist 
cell death induced by chemotherapy or radiation. Among the 
processes activated during tumor growth, metabolism, and more 
specifically glycolysis, is the one that is the most exacerbated by 
hypoxia (5, 6). To counterbalance mitochondrial generation of 
ROS that interfere with cell survival, HIF-1 activates pyruvate 
dehydrogenase kinase (PDK1) to block the conversion of 
pyruvate to acetyl CoA resulting in decreased flux through the 
tricarboxylic acid (TCA) cycle (7, 8). Moreover, HIF-1 upregu-
lates the expression of COX4-2, present in complex IV, and the 
mitochondrial protease LONP1, which in turn degrades COX4-1. 
COX4-2 is then more efficient at facilitating electron transfer 
to O2 and thereby protects the cell from oxidative damage in 
hypoxia (9). HIF-1-mediated inhibition of MYC (10) and PGC-1 
also results in reduced mitochondrial biogenesis (11). However, 
cancer cells have selectively found new mechanisms that promote 
their survival.
In this mini review, we highlight a new hypoxic mechanism 
that modulates the amount (decrease) and structure (a cleaved 
form lacking its C-terminus) of the most abundant protein of 
the outer mitochondrial membrane (12), the voltage-dependent 
anion channel (VDAC), which profoundly impacts cancer cell 
proliferation and survival.
THe vOLTAGe-DePenDenT AniOn 
CHAnneL: FUnCTiOn, ORGAniZATiOn, 
AnD STRUCTURe
Voltage-dependent anion channel plays a key role in both mito-
chondrial metabolism and cell death, acting as a convergent point 
of control (13, 14). The function of VDACs as a pore seems quite 
clear-cut, but other suspected more complex functions are yet to 
be elucidated. VDACs play a crucial role as a gatekeeper for the 
entry and exit of many metabolites. They mediate and gate the 
flux of small ions (Cl−, K+, Na+) with a preference for anions and 
metabolites (NADH, citrate, succinate, glutamate, pyruvate, and 
glucose) and act as channels that constitute the main pathway 
for passage of ATP/ADP (15–18). In addition to their role in 
bioenergetics, VDACs act as a scaffold through interactions with 
numerous proteins. They are anchors for pro- and anti-apoptotic 
proteins, respectively, of the hexokinase (HK) (19, 20) and Bcl-2 
families (21–24) of proteins, which contribute to the balance 
between survival and cell death.
Voltage-dependent anion channels exist as three isoforms: 
VDAC1, VDAC2, and VDAC3, encoded by three different 
genes. The three human VDAC genes share the same number 
of exons for each gene isoform (25). The human VDAC1 gene 
spans about 30 kb localized on the chromosome 5q31-32 (26), 
the human VDAC2 has been mapped to chromosome 10q22 and 
is 16.4 kb in length whereas the human VDAC3 is localized on 
chromosome 8p11.21 with a length of 14.3 kb. The VDAC2 gene 
uses several polyadenylation sites, thus giving rise to multiple 
mRNA, whereas the VDAC3 gene presents an alternative splic-
ing event that corresponds to an additional ATG. At the protein 
level and in mammals, VDACs share ~70% identity with a very 
similar molecular mass of 30–35  kDa. They are known to be 
expressed ubiquitously in mammalian mitochondria, where 
VDAC1 remains the most abundantly expressed of the three 
isoforms (27). VDAC1 has also been detected in the plasma 
membrane of human lymphocytes (27, 28) and in the sarco-
plasmic reticulum (29).
Analysis of the structure of VDACs revealed a 19-stranded 
β-barrel fold (13), yet only 13 of these strands form the wall of the 
channel. The N-terminal region of VDACs is very dynamic and 
exposed to the cytoplasm but located inside the pore. It acts as 
the voltage sensor and maintains the channel in an open or closed 
status (25). In an open-state configuration, VDACs are capable of 
passing millions of ATP molecules per second in vitro (17) and up 
to 100,000 ATP molecules per second under physiological condi-
tions (16, 17), using at least five different trajectories (30). By 
contrast, very little is known about the function of the C-terminus 
of VDACs. It possesses NAD+-binding sites, considered essential 
for glycolysis (31). Finally, VDAC1 can oligomerize and assemble 
into a dynamic equilibrium of dimers, trimers, tetramers, and 
higher oligomers (32). These conformational changes could 
occur upon induction of apoptosis (33). However, the function 
of VDAC1 oligomers is not known. They may contribute to the 
stabilization of the protein (34) and may offer a more stable 
platform to anchor HKs I and II (32).
THe vOLTAGe-DePenDenT AniOn 
CHAnneL: MODiFiCATiOnS, SiLenCinG, 
AnD OveR-eXPReSSiOn
Post-translational modifications, changes in expression, or 
even mutation in VDACs profoundly disrupt metabolism and, 
thus, the balance between cell survival and cell death. The 
three isoforms of VDAC can be post-translationally modi-
fied by phosphorylation and acetylation at multiple sites (35). 
The role of VDAC1 phosphorylation remains unclear, as it is 
difficult to study these modifications on highly hydrophobic 
integral mitochondrial outer membrane proteins. The impact of 
these modifications has been studied mostly in the context of 
apoptosis. However, no direct relationship to VDAC function 
or activity has been demonstrated. The relevance of acetylation 
remains to be determined. Recently, our studies showed a new 
form of post-translational modification of VDAC1; C-terminal 
truncation of the protein to give VDAC1-ΔC (discussed in 
Section “The Hypoxic Mitochondrial Phenotype and VDAC1-
ΔC”) (Figure 1). This modification occurred specifically under 
hypoxic conditions. This hypoxic form was associated in some 
cancer cell lines with resistance to chemotherapy-induced apop-
tosis, a higher output of ATP and was found in late stage tumors 
of patients with lung cancer (36). A mutation in VDAC1 that 
resulted in the removal of 60% of the length of the C-terminal 
region has been described in colorectal and gastric cancers, 
but the consequence on metabolism and apoptosis is still to be 
determined (37).
Deletion of genes coding Vdac in mice models has provided 
information concerning the functions of VDACs. Vdac1 and 
FiGURe 1 | A HiF- and TP53/73-dependent model that potentiates tumor cell survival in hypoxia through the formation of enlarged mitochondria that 
interact with endolysosomes to modify mitochondrial vDAC1, an ATP channel-regulating metabolism and apoptosis. As oxygen diffuses from a vessel, 
a decreasing gradient in the oxygen concentration occurs in the adjacent tissue (top). As the level in oxygen decreases, resistance to radiotherapy and 
chemotherapy increases since the former requires oxygen for DNA damage, and the latter depends on the limits of tissue diffusion of the drug. Hypoxic cells with 
resistance to chemotherapy show the presence of enlarged hypoxic mitochondria (magnified on the bottom left). Microfusion between the mitochondrial outer 
membrane and an endolysosomal membrane takes place (magnified on the bottom right), and a cleaved form of VDAC1 is produced, according to the following 
steps: (1) VDAC1 is exposed to an endolysosome, (2) a complex formed of BNIP3/Mieap (mitochondrial proteins) and clathrin (endolysosomal protein) maintained 
microfusion of both membranes, (3) the endolysosomal asparagine endopeptidase (AEP), in contact with the mitochondrial outer membrane, specifically cleaves 
VDAC1, and (4) VDAC1-ΔC promotes resistance to apoptosis and a blockade in cytochrome c release.
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Vdac3 heterozygote embryonic stem cells have been generated to 
obtain hetero- and homozygote knockout mice (38, 39). Vdac1−/− 
mice did not meet the normal Mendelian pattern, suggesting 
partial embryonic lethality at days 10.5–11.5. For the mice that 
survived, multiple respiratory defects appeared in skeletal and 
cardiac muscles. The mice were fertile but were retarded in growth. 
Mitochondria from muscle fibers of skin contained enlarged 
mitochondria with very compact cristea. Vdac3−/− mice survived 
with defects in mitochondrial respiration in heart tissue. Males 
were also infertile with alterations to their sperm. A combination 
of both Vdac1−/− and Vdac3−/− deletions was not lethal. Finally, the 
homozygote mice lacking Vdac2 died during development (40). 
Although it seems surprising not to find VDACs in a tissue, we 
recently reported, using the Cancer Genome Atlas (TCGA) data 
sets from 89 cancer studies, that deletion of the VDAC1 gene is 
found in some cancer types (41). Even if the VDAC1 gene was 
mainly heterologously lost, some homologous loss was found. 
Clear cell renal cell carcinoma (ccRCC) and ovarian cancers 
seemed to be the most affected by the homologous loss of the 
VDAC1 gene, whereas the heterologous loss was almost ubiq-
uitous. It might be interesting to further examine these data to 
check if the VDAC2 and VDAC3 genes are also deleted or if com-
pensation has taken place to counterbalance for the homologous 
loss of VDAC1. New aspects of the function of VDAC1 were high-
lighted in our recent transcriptome analysis of mouse embryonic 
fibroblasts (MEFs) knocked out for Vdac1 (41). We characterized 
the cellular and molecular phenotype of both Vdac1−/− MEF and 
MEFs transformed with the pBabe-RASv12 vector, Vdac1−/− RAS 
MEF. Our results pointed to alterations in programs controlling 
HIF-1, cell death, and survival, as well as cell proliferation and 
motility. We confirmed the presence of alterations in OXPHOS 
and glycolysis in knocked out cells, which was accompanied by 
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a higher level of apoptosis. Of note, Vdac1−/− MEF and Vdac1−/− 
RAS MEF grew better in hypoxia, by maintaining respiration and 
promoting glycolysis. Vdac1−/− RAS MEF formed tumors faster 
than Wt RAS MEF in nod-scid mice. Moreover, after dissection 
of the various mechanisms involved, our results showed a strong 
impact of VDAC1 on tumor development, through alterations in 
the inflammatory response as a result of an abnormal vascula-
ture due to ROS production and HIF-1α stabilization. Changes 
in metabolism were also observed in both Vdac1−/− MEF and 
Vdac1−/− RAS MEF. The first surprise came from the impact of 
hypoxia on the behavior of Vdac1−/− cells, in particular on cell 
proliferation. These initial results lead us to revisit the Mendelian 
ratio observed in the Vdac1−/− mice. Indeed, a large number of 
Vdac1−/− embryos did not survive (60%), whereas the Vdac1−/− 
embryos that survived gave an almost normal phenotype. Is it 
possible that the non-viable Vdac1−/− embryos were not exposed 
to low oxygen concentrations during development and, therefore, 
apoptosis prevailed? Our second hypothesis is that non-viable 
Vdac1−/− embryos may have developed dysfunctional blood ves-
sels during embryogenesis. The second surprise came from our 
result that suggested the involvement of VDAC1 in modulating 
the structure of blood vessels and in enhancing the inflammatory 
response (41). Indeed, accumulation of ROS in Vdac1−/− RAS 
MEF-derived tumors triggered HIF-1α stabilization, abnormal 
vasculature, and leakage of red blood cells, thus generating an 
inflammatory response that resulted on a strong impact on 
VDAC1 tumor development. To our knowledge, this is the first 
time that VDAC1 has been connected to such events. These 
pathways should not be neglected in the future when considering 
VDAC1 as a therapeutic target.
Exogenous over-expression of VDAC1 in different cell lines 
always seems to be linked to apoptosis (24, 25, 42, 43). However, 
the impact of VDAC1 directly or indirectly on apoptosis is not 
yet clear. It may depolarize the inner membrane (44) as it could 
trigger the mitochondrial permeability transition pore (MPTP) 
(45). However, we showed that VDAC1 was over-expressed in 
lung adenocarcinomas tumor tissue from 44 patients (36). More 
recently, after analysis of the same TCGA data sets, as described 
above, expression of Vdac1 was also gained and amplified (41). 
The in  vitro results contrast with the in  vivo ones. It is easy to 
hypothesize that as VDAC1 regulates metabolism through its 
association with HK, cancer cells draw a substantial profit from 
increasing glycolysis. Similarly, because of its association with 
members of the Bcl-2 family, cancer cells, again, take advantage 
of such an association by minimizing apoptosis.
THe HYPOXiC MiTOCHOnDRiAL 
PHenOTYPe AnD vDAC1-ΔC
Mitochondria are dynamic organelles that undergo membrane 
remodeling through cycles of fusion and fission (Figure  1). 
This balance controls the mitochondrial structure and, thus, 
mitochondrial activity. The key factors regulating fusion are the 
dynamin-related GTPases mitofusin 1 (Mfn1) and 2 (Mfn2), 
and optic atrophy 1 (OPA1) that mediate the OMM, while 
the dynamin-related protein 1 (DRP1) regulates the oppos-
ing process of fission of the inner mitochondrial membrane 
(IMM) (46). Cells lacking mitochondrial fusion show changes 
in mitochondrial shape associated with a loss of their mem-
brane potential, a reduced growth rate, and a lower activity 
of respiratory complexes (47). By contrast, forced expression 
of Mfns resulted in the formation of clusters with enlarged 
mitochondria due to the fusion of the OMM (48). In 2010, 
we reported that a number of human cancer cells, including 
colon carcinoma cells (LS174) and non-neoplastic CCL39 
lung fibroblasts exposed to long-term hypoxia (72 h – 1% O2) 
showed a change in mitochondrial phenotype from a tubular 
network to an enlarged morphology (49). The modification of 
the shape of mitochondria observed in LS174 cells was HIF-1-
dependent (36). The formation of these enlarged mitochondria 
resulted from hyperfusion as expression of Mfn1 was increased 
in hypoxia and as silencing of the expression of Mfn1 reverted 
the mitochondrial morphology. Moreover, we reported that 
Bcl-2/adenovirus E1B 19-kDa interacting protein (BNIP3) 
and BNIP3 like (BNIP3L), two pro-autophagy proteins from 
the Bcl-2 family, also participated in the dynamic process of 
fusion induced in hypoxia. Finally, cytochrome c was retained 
inside these structurally unusual mitochondria when the cells 
were treated with staurosporine, a pro-apoptotic drug. We 
concluded that cells with enlarged mitochondria were more 
resistant to cell death than normoxic cells and that these cells 
possessed a selective growth advantage.
We were, therefore, faced with the challenge of exploring the 
underlying mechanisms that lead to the protective phenotype 
of hypoxic cancer cell. We found that VDAC1 was detected in 
hypoxia as a smaller than usual form (26 kDa rather than 30 kDa 
on SDS-PAGE). The amount of the 30 kDa form was decreased by 
around 50% with a parallel increase in the smaller 26 kDa form 
in hypoxia. Using a VDAC1 antibody directed to the C-terminus 
of VDAC1 that did not detect this fast migrating form of VDAC1 
on immunoblots (36) and after analysis by mass spectrometry 
(50), we concluded that it was a form truncated in the C-terminal 
region: VDAC1-ΔC. After reconstitution into a planar lipid 
bilayer system, VDAC1-ΔC presented a similar but not identical 
channel activity and voltage dependency as VDAC1. At a higher 
voltage of −40  mV, the full-length channel showed two major 
conducting states with higher occupancy at the closed substate, 
whereas VDAC1-ΔC showed a higher open-state occupancy 
in comparison to the occupancy of low-conducting substates. 
Moreover, at the high voltages, VDAC1-ΔC showed a slightly 
higher conductance than VDAC1 (36). Indeed, we observed an 
increase in ATP levels in cells in hypoxia when VDAC1-ΔC and 
enlarged mitochondria were present. We also demonstrated that 
VDAC1-ΔC associated with the same partners as VDAC1, i.e., 
HKI/II and Bcl-XL. Anchoring of HKI/II is probably involved 
in the exacerbated metabolism of tumor cells in hypoxia in the 
presence of VDAC1-ΔC. Both the association of VDAC1-ΔC 
with HK and the increase in the expression of HKI/II in hypoxia 
increased OXPHOS and glycolysis. Thus, VDAC1-ΔC seems to 
control cell survival in hypoxia by regulating the export of ATP 
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and probably NADH and brings advantage to cancer cells in 
promoting survival via mitochondria that are probably not as 
dormant as previously described. We do not know yet whether 
the conformation and the oligomerization of VDAC1-ΔC are 
different to that of VDAC1.
The VDAC1–HK complex has been reported to also play 
an important role in apoptosis (14). Thus, the VDAC1–HK 
complex already represents a target for cancer therapy, using, 
for example, specific VDAC1-based peptides that disrupt the 
connections between these proteins (51). HK provides an 
apoptosis-suppressive capacity by interfering with the ability 
of Bax to bind to mitochondria and induce apoptosis (52, 53). 
In addition, Bcl-XL, which interacts with VDAC1-ΔC (36), was 
found to protect cells from apoptosis via a block in the Bax–Bak 
interaction, subsequently preventing cytochrome c release (54, 
55). Currently, cytochrome c is considered to play an important 
role in the resistance to cell death observed in cells with enlarged 
mitochondria and VDAC1-ΔC. We have previously shown 
that resistance to chemotherapy was linked to the phenotype 
of enlarged mitochondria. Subsequently, we demonstrated that 
silencing of VDAC1/VDAC1-ΔC in hypoxia or re-exposure of 
cells to normoxia, which inhibited the formation of VDAC1-
ΔC, restored the sensitivity of the cells to apoptosis. We also 
showed that the mitochondrial transmembrane potential was 
unchanged in hypoxia and that cytochrome c was not released 
in the presence of staurosporine-induced apoptosis, whereas the 
transmembrane potential was decreased in normoxic cells under 
these conditions. We showed that cytochrome c was trapped 
inside the mitochondrial intermembrane space due to a change in 
the mitochondrial conformation and a hypothetical modification 
to VDAC oligomerization. These interactions occur specifically 
in hypoxia, when cancer cells are known to be highly resistant 
to anti-cancer treatments, and may, therefore, be exploited for 
therapy in the future.
Finally, we investigated further the mechanism behind the 
hypoxic regulation of the truncated form of VDAC1. We found 
that the cleavage of VDAC1 was dependent on TP53 or p73 
as only cells expressing p53 (LS174, A549, or HepG2 cells) or 
p73 (HeLa cells) contained the hypoxic VDAC1-ΔC. Moreover, 
silencing of TP53 and/or HIF-1α diminished VDAC1 truncation 
and, thus, cell survival in the presence of staurosporine. Mieap, a 
TP53-inducible protein that controls mitochondrial quality was 
also involved, as silencing of MIEAP diminished also the hypoxic 
VDAC1-ΔC. We found that bafilomycin A1 and chloroquine, 
two compounds that increase the lysosomal pH, inhibited the 
cleavage of VDAC1 to VDAC1-ΔC, suggesting implication of 
lysosomes. This was confirmed by electron microscopy, which 
showed microfusion between mitochondria and endolysosomes 
and by cleavage of VDAC1 by an endolysosomal asparagine 
endopeptidase (AEP). Analysis by mass spectrometry of 
VDAC1-ΔC showed cleavage at asparagine 214 and glycine 
213. Of note, AEP is also regulated by TP53 (56). Moreover, we 
reported that BNIP3, already known to be involved in regulating 
mitochondria morphology in hypoxia (36), acted as a docking 
site for lysosomes together with clathrin, a protein involved 
in multiple membrane vesicle trafficking pathways (57). This 
mechanism was identified not only in  vitro but also in  vivo in 
patients with lung cancer. We propose that this novel mechanism 
is a readout of mitochondrial–endolysosomal microfusion in 
hypoxia, in vitro and most importantly in vivo, and represents an 
additional defense mechanism that cancer cells have developed 
to resist chemotherapy.
TARGeTinG vDAC1 FOR THeRAPY
Studies into cellular metabolism have lead to the characterization 
of a number of drugs that have already showed promise in pre-
clinical and clinical trials. However, the quest for new therapeutic 
targets is hampered by the fact that cells show a great degree of 
plasticity, which already augurs the challenges we face. Studying 
metabolism per se is important and will allow us to identify new 
targets. However, metabolism should be studied in the context 
of a changing microenvironment (hypoxia, pH, changes in con-
centrations of metabolites, etc.) and in the context of malignant 
transformation. Thus, VDAC1-ΔC appears to be an interesting 
therapeutic target. Various compounds have already been identi-
fied for their capability to directly interact with and modify the 
activity of VDAC. Avicins (closes VDAC) (58), acrolein (used in 
Alzheimer’s disease to carbonylate VDAC) (59), erastine (binds 
to VDAC2) (60), endostatin (inducing PTP opening) (61), fluox-
etine and cisplatin (inhibition of PTP opening and apoptosis) (62, 
63), furanonaphthoquinones (induces VDAC-dependent apop-
tosis) (64), and oblimersen (blocks channel activity) (65, 66) are 
chemicals that will be tested under hypoxic conditions in the near 
future. In addition, VDAC-based peptides, novel pro-apoptotic 
agents that specifically target domains for interaction with HK, 
Bcl-2, and Bcl-XL, could be an interesting alternative to chemicals 
to restore the sensitivity to apoptosis in hypoxia (67).
We hope that, in the near future, this hypoxia/VDAC1-ΔC duo 
will meet the expectations that we have discussed in this review.
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